We are live on ! Find out more
CATX icon

Perspective Therapeutics

30 hedge funds and large institutions have $1.18M invested in Perspective Therapeutics in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

3% more funds holding

Funds holding: 2930 (+1)

0.04% less ownership

Funds ownership: 0.59%0.55% (-0.04%)

27% less capital invested

Capital invested by funds: $1.62M → $1.18M (-$440K)

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.66%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
6
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change

CATX Hedge Fund Activity: Q3 2019 in Review

30 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q3 2019, worth a combined $1.18M — down 27% from $1.62M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CATX positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $24.5K. The largest seller was Sabby Management, exiting entirely with an estimated $152K sold.

  • 30 institutional investors held Perspective Therapeutics (CATX) as of Q3 2019, up from 29 in Q2 2019.
  • Funds reported $1.18M of Perspective Therapeutics stock for Q3 2019, down 27% quarter-over-quarter.
  • 5 funds opened new Perspective Therapeutics positions in Q3 2019 and 3 closed out, a net change of +2 holders.
  • The largest Perspective Therapeutics buyer in Q3 2019 was Virtu Financial, an estimated $24.5K added.
  • The largest Perspective Therapeutics seller in Q3 2019 was Sabby Management, an estimated $152K sold.

Based on aggregated 13F filings for Q3 2019.